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OBJECTIVES: To determine the degree to which hyper-
glycemia predicts the development of frailty and lower
extremity mobility limitations.
DESIGN: Secondary data analysis of longitudinal data
collected in a prospective cohort study.
SETTING: Baltimore, Maryland.
PARTICIPANTS: Three hundred twenty-nine women
from the Women’s Health and Aging Study II aged 70 to
79 at baseline who had all variables needed for analysis.
MEASUREMENTS: Glycosylated hemoglobin (HbA1c) at
baseline, categorized as less than 5.5%, 5.5% to 5.9%,
6.0% to 6.4%, 6.5% to 7.9%, and 8.0% and greater, was
the independent variable. The incidence of frailty and
lower extremity mobility limitations (based on self-
reported walking difficulty, walking speed, and Short
Performance Physical Battery score) was determined
(follow-up  9 years). Frailty was assessed using the
Cardiovascular Health Study criteria. Covariates included
demographic characteristics, body mass index, interleukin-
6 level, and clinical history of comorbidities. Statistical
analyses included Kaplan–Meier survival curves and Cox
regression models adjusted for important covariates.
RESULTS: In time-to-event analyses, HbA1c category was
associated with incidence of walking difficulty (P = .049)
and low physical performance (P = .001); association with
incidence of frailty and low walking speed had a trend
toward significance (both P = .10). In regression models
adjusted for demographic characteristics, HbA1c of 8.0%
or greater (vs < 5.5%) was associated with an approxi-
mately three-times greater risk of incident frailty and three
to five times greater risk of lower extremity mobility limi-
tations (all P < .05). In fully adjusted models, HbA1c of
8.0% or greater (vs < 5.5%) was associated with incident
frailty (hazard ratio (HR) = 3.33, 95% confidence interval
(CI) = 1.24–8.93), walking difficulty (HR = 3.47, 95%
CI = 1.26–9.55), low walking speed (HR = 2.82, 95%
CI = 1.19–6.71), and low physical performance
(HR = 3.60, 95% CI = 1.52–8.53).
CONCLUSION: Hyperglycemia is associated with the
development of frailty and lower extremity mobility limita-
tions in older women. Future studies should identify medi-
ators of these relationships. J Am Geriatr Soc 60:1701–
1707, 2012.
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Diabetes mellitus in elderly adults is a growing publichealth concern, with almost two-thirds of older U.S.
adults having diabetes mellitus or pre-diabetes mellitus.1
The numbers of persons with diabetes mellitus will almost
double by 2030.2 In older people, diabetes mellitus can
have a significant effect on physical functioning and has
been associated with lower extremity mobility limita-
tions.3,4 Diabetes mellitus has also been associated with
frailty, a geriatric condition of physiological vulnerability
to stressors associated with adverse outcomes such as dis-
ability and mortality,5–8 but whether hyperglycemia per se
predicts the development of frailty or lower extremity
mobility limitations has not been fully described.
Cross-sectional studies have previously demonstrated
that hyperglycemia is associated with frailty.9 Different
dynamics of glucose and insulin in response to a glucose
challenge have also been reported in frail and nonfrail
women, with 2-hour post-oral glucose tolerance test
(OGTT) levels of glucose and insulin better discriminating
frailty status than fasting values,8 although the direction of
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the association between frailty status and abnormalities in
glucose metabolism remains unclear. Longitudinal associa-
tions between insulin resistance and incident frailty have
been described in the Cardiovascular Health Study
(CHS).10 Nonetheless, the use of short-term fasting mea-
sures of glycemia have limited these studies, whereas bio-
markers such as glycosylated hemoglobin (HbA1c), which
reflect exposure to glucose over the past 3 months and are
influenced by fasting and postprandial hyperglycemia, may
be less variable. Hyperglycemia has also been found to be
cross-sectionally associated with lower extremity disabil-
ity4,9 but to the knowledge of the authors of the current
study, associations between hyperglycemia and declines in
lower extremity mobility function over time have not been
previously explored.
The goal of the present study was to describe the
association between hyperglycemia and incident frailty
and lower extremity mobility limitations in a longitudi-
nal cohort of older, community-dwelling women. The
hypotheses were that hyperglycemia (assessed according
to HbA1c) would predict the development of frailty
and lower extremity limitations; that the association
between hyperglycemia and frailty and lower extremity
limitations would be independent of potential con-
founders; and that the association between hyperglyce-




The study population consisted of women aged 70 to 79
at baseline enrolled in the Women’s Health and Aging
Study II who represented the two-thirds least disabled
women living in the community.11 Four hundred thirty-six
women were enrolled at baseline and assessed at seven
study visits from 1994 to 2008; 382 had information on
HbA1c levels available at baseline. After excluding partici-
pants with missing covariates (n = 11), stroke or Parkin-
son’s disease (more likely to have lower extremity
limitations due to primary disease; n = 5), or HbA1c levels
less than 4.5% (n = 2), 364 women remained. The
excluded women did not differ significantly from those
included in the study.
For incident frailty analysis, women who had the out-
come (frailty) at baseline (n = 11), missing outcome
(frailty) status at baseline (n = 2), or no follow-up
(n = 22) were also excluded, leaving 329 women available
for this analysis. The total number of participants who
completed study visits was as follows: two visits (n = 25),
three visits (n = 58); four visits (n = 22); five visits
(n = 26); six visits (n = 74); and all seven visits (n = 124).
Similar exclusion criteria were used for lower
extremity outcomes, which resulted in the following ana-
lytical samples to examine incidence of self-reported
walking difficulty (n = 329); low walking speed, defined
as a level in the lowest quartile (<0.82 m/s) for the study
population (n = 259); and low physical performance,
defined as a Short Physical Performance Battery (SPPB)
score in the lowest quartile (<9) for the study population
(n = 267).
Variables
The main outcome was frailty as described by Fried and
colleagues.5,6 Five criteria were used: shrinking (body mass
index (BMI) <18.5 kg/m2 or  5% annual weight loss),
weakness (low grip strength), poor endurance (exhaus-
tion), slowness (low walking speed), and physical inactiv-
ity. Those with no criteria were categorized as nonfrail,
one or two criteria as prefrail, and three or more criteria
as frail.
Lower extremity mobility outcomes included subjec-
tive and objective measures. Participants self-reported any
difficulty walking one-quarter of a mile at all visits. Walk-
ing speed was calculated based on a usual-pace 4-m mea-
sured walk test at all visits. Assessment of the SPPB,
consisting of chair stands, walk test, and tandem stands
for balance, was available for all visits except visit 4, and
scores were calculated using criteria defined previously and
adapted for clinical use.12–14
The main exposure of interest was HbA1c. Nonfasting
blood samples were obtained and HbA1c measured using
a BioRad assay (Hercules, CA) from frozen whole blood.9
Demographic information was obtained using a stan-
dardized questionnaire. Height and weight were measured
to calculate BMI. BMI was categorized according to World
Health Organization criteria as underweight (<18.5 kg/
m2), normal (18.5–24.9 kg/m2), overweight (25.0–29.9 kg/
m2), and obese ( 30 kg/m2).15 For the analysis of inci-
dent walking difficulty only, underweight was categorized
as less than 20 kg/m2, because all women with BMI less
than 18.5 kg/m2 developed walking difficulty. Interleukin
(IL)-6 was measured from frozen serum using a commer-
cial enzyme-linked immunosorbent assay (Quantikine
Human; R&D Systems, Minneapolis, MN). History of dia-
betes mellitus, coronary artery disease, osteoarthritis and
chronic obstructive pulmonary disease was self-reported.
Coronary artery disease included congestive heart failure,
myocardial infarction, and angina pectoris.
Peripheral arterial disease was defined as an ankle–
brachial index less than 0.9.3 Peripheral neuropathy was
defined according to physician report or inability to feel
the complete vibration of a 128 Hz tuning fork in either
great toe.
Statistical Analysis
Baseline characteristics were compared according to inci-
dent frailty status using the chi-square test or Student t-
test. Incidence was defined as first occurrence of each event
in all analyses. Kaplan–Meier survival curves explored the
association between HbA1c (categorized to account for
potential nonlinear relationships into <5.5%, 5.5–5.9%,
6.0–6.4%, 6.5–7.9%, 8.0%) and time to event for
frailty and lower extremity outcomes. HbA1c categories
were chosen based on previous studies suggesting greater
risk of mortality at the highest and lowest thresholds,16,17
with cutoffs for the intermediate categories based on diag-
nostic criteria for diabetes mellitus.18 Cox regression mod-
els for discrete time outcomes were constructed to
characterize the independent association between HbA1c
at baseline and outcomes in the following sequential
models: Model 1: adjusted for demographics (age, race,
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education), Model 2: adjusted for Model 1 plus BMI,
Model 3: adjusted for Model 2 plus IL-6, Model 4:
adjusted for Model 3 plus comorbidities (coronary artery
disease, osteoarthritis, chronic obstructive pulmonary dis-
ease, peripheral arterial disease, peripheral neuropathy).
For the frailty model, sensitivity analyses were performed
adjusting for prefrailty status at baseline. Potential qua-
dratic associations between HbA1c and incident frailty or
other outcomes were explored in regression models, but
because none were found, the lowest HbA1c category
(<5.5%) was chosen as the reference for all analyses. The
statistical program used was SAS 9.2 version (SAS Insti-
tute, Inc., Cary, NC).
RESULTS
Seventy-seven of 329 women (23%) developed incident
frailty during a mean follow-up of 8.6 ± 3.6 years. Within
the baseline nonfrail cohort, 70 women (21.3%) died, and
57 (17.4%) dropped out before frailty development. The
women who did and did not develop frailty were similar
with respect to age, race, and education (Table 1). A sig-
nificant difference in the distribution of BMI categories
was found between groups (P = .01), with a greater pro-
portion of women being obese or underweight in the
group that developed frailty. Not surprisingly, a greater
proportion of women were prefrail at baseline in the inci-
dent frailty group than in the nonfrail group (55.8% vs
29.4%; P < .001). There were no significant differences in
the clinical history of other comorbidities (all P > .05).
Inflammatory markers (IL-6) were largely similar, whereas
mean HbA1c tended to be higher in women who devel-
oped incident frailty (6.2%) than in those who did not
(6.0%, P = .07).
For lower extremity limitations, 27% of women devel-
oped self-reported walking difficulty (mean follow-up
8.4 ± 3.7 years), 63% of women developed low walking
speed (mean follow-up 8.8 ± 3.5 years), and 67% devel-
oped low physical performance (mean follow-up
8.8 ± 3.5 years). The overall incidence rate for frailty and
lower extremity limitations during follow-up per 100 per-
son-years was 2.26 (95% confidence interval (CI) = 1.78–
2.83) for frailty, 2.78 (95% CI = 2.24–3.42) for walking
difficulty, 8.46 (95% CI = 7.20–9.88) for low walking
speed, and 8.61 (95% CI = 7.40–9.97) for low physical
performance.
Kaplan–Meier survival curves were next examined for
time-to-event analyses (Figure 1A–D ). The women were
divided into the following HbA1c categories for incident
frailty analysis: less than 5.5% (n = 64), 5.5% to 5.9%
(n = 135), 6.0% to 6.4% (n = 77), 6.5% to 7.9%
(n = 38), and 8.0% or greater (n = 15). Similar HbA1c
categories were used for lower extremity outcomes. HbA1c
category was associated with probability of developing
frailty (P = .10) and low walking speed (P = .10),
although the results were not statistically significant based
on the log-rank test (Figure 1A, C). Nevertheless, HbA1c
category was significantly associated with probability of
developing incident walking difficulty (Figure 1B, P = .049)
and low physical performance (Figure 1D, P = .001).
The association between HbA1c category and incident
frailty was further explored in regression models (Table 2).
HbA1c of 8.0% or greater was significantly associated
with incident frailty after adjusting for demographic
characteristics (hazard ratio (HR) = 3.63, 95% CI =
1.41–9.33; Model 1) compared to the reference category
(HbA1c < 5.5%). This association was slightly attenuated
after further adjustment for BMI and IL-6 but essentially
unchanged. After adjustment for comorbidities, the associ-
ation remained significant (HR = 3.33, 95% CI = 1.24–
8.93; Model 4). In sensitivity analyses, prefrailty was fur-
ther adjusted for in the fully adjusted model to explore its
contributions as a potential confounder;9 the association
was attenuated such that it was no longer significant
(HR = 2.64, 95% CI = 0.95–7.34). However, prefrailty
may also contribute as a mediator of the association
between HbA1c and incident frailty in women who are
nonfrail at baseline.
HbA1c of 8.0% or greater was also associated with
significantly more difficulty in walking after adjustment for
Table 1. Selected Baseline Participant Characteristics













Age, mean ± SD 73.9 ± 2.8 74.0 ± 2.9 73.9 ± 2.8 .62
White,% 83.9 83.1 84.1 .83
Education, years,
mean ± SD
12.6 ± 3.3 12.2 ± 2.9 12.8 ± 3.4 .17
Body mass index, kg/m2 (%)
<18.5 3.3 6.5 2.4 .01
18.5–24.9 36.2 29.9 38.1
25.0–29.9 38.9 31.2 41.3
 30.0 21.6 32.5 18.3
Mean ± SD 26.6 ± 5.1 27.3 ± 5.5 26.4 ± 4.9 .16
Clinical history,%
Prefrailty 35.6 55.8 29.4 <.001
Osteoarthritis 66.9 66.2 67.1 .89
Chronic obstructive
pulmonary disease
23.4 26.0 22.6 .54
Coronary artery
disease
13.7 16.9 12.7 .35
Peripheral arterial
disease
4.6 7.8 3.6 .12
Peripheral
neuropathy
7.0 7.8 6.8 .76
Known diabetes
mellitus
7.6 9.1 7.1 .57
Laboratory measure
Interleukin-6, pg/
mL, mean ± SD
3.9 ± 4.8 4.2 ± 7.0 3.8 ± 3.9 .49
Glycosylated hemoglobin (%)
<5.5% 19.5 15.6 20.6 .24
5.5–5.9% 41.0 40.3 41.3
6.0–6.4% 23.4 24.7 23.0
6.5–7.9% 11.6 10.4 11.9
 8.0% 4.5 9.1 3.2
Mean ± SD 6.0 ± 0. 9 6.2 ± 1.1 6.0 ± 0.8 .07
BMI = body mass index; SD = standard deviation.
a Comparing participants with incident frailty to those without incident
frailty.
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demographic characteristics (HR = 5.03, 95% CI = 1.91–
13.27; Model 1) compared to the reference category
(Table 2). This association was moderately attenuated but
remained significant after adjustment for BMI (HR = 2.93,
95% CI = 1.08–7.96; Model 2), IL-6 (HR = 2.91, 95%
CI = 1.07–7.91; Model 3), and comorbidities (HR = 3.47,
95% CI = 1.26–9.55; Model 4). HbA1c of 6.5% to 7.9%
was also significantly associated with incident walking dif-
ficulty in models adjusted for demographic characteristics
(HR = 2.26, 95% CI = 1.05–4.87; Model 1), suggesting a
possible graded association between HbA1c level and
incident walking difficulty, although this was no longer
statistically significant in fully adjusted models (Model 4).
Similarly, HbA1c level of 8.0% or greater was associ-
ated with development of low walking speed after adjust-
ment for demographic characteristics (HR = 3.14, 95%
CI = 1.35–7.34; Model 1), BMI (HR = 2.89, 95% CI =
1.23–6.81; Model 2), IL-6 (HR = 2.70, 95% CI = 1.15–
6.33; Model 3), and comorbidities (HR = 2.82, 95% CI =
1.19–6.71) compared to HbA1c <5.5%.
Last, HbA1c of 8.0% or greater (versus reference) was
associated with development of poor physical performance
after adjustment for demographic characteristics
(HR = 3.31, 95% CI = 1.43–7.69), BMI (HR = 3.25, 95%
CI = 1.38–7.66), IL-6 (HR = 3.09, 95% CI = 1.31–7.28),
and comorbidities (HR = 3.60, 95% CI = 1.52–8.53).
DISCUSSION
Participants in the highest HbA1c category (8.0%) had
a statistically significantly three times greater risk of devel-
oping frailty and three to five times greater risk of develop-
ing lower extremity mobility limitations after adjustment
for demographics than those in the lowest category
(<5.5%). The association between HbA1c and incident
frailty and lower extremity mobility limitations remained
independent of potential confounders and was nonlinear,
with most events occurring in the highest HbA1c category
( 8.0%), suggesting that hyperglycemia, particularly in
the diabetic range, can predict the onset of incident frailty
and lower extremity mobility limitations less than a decade
later.
To the knowledge of the authors, the association
between hyperglycemia and incident frailty has been
explored in only one other study.11 In that study, homeo-
stasis model of insulin resistance (HOMA-IR) was calcu-
lated based on fasting glucose and insulin. For every
standard deviation increment in HOMA-IR, the adjusted
HR for frailty was 1.15 (95% CI = 1.02–1.31). In com-
parison, the current study found that the association
between HbA1c and incident frailty was nonlinear. An
advantage of HbA1c is that postprandial hyperglycemia,
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Figure 1. Kaplan–Meier curves demonstrating the time to event of outcomes during follow-up for older women categorized
according to level of baseline glycosylated hemoglobin (HbA1c): <5.5% (thin solid line ), 5.5–5.9% (thick solid line ),
6.0–6.4% (thin dashed line ), 6.5–7.9% (thick short and long dashed line ), and  8% (thick short dashed line ).
The association between HbA1c category and probability of survival for the outcomes are (A) frailty (P = .10); (B) self-reported
walking difficulty (P = .049); (C) slow walking speed (P = .10); and (D) low Short Physical Performance Battery score
(P = .001). The x-axis shows the time to event in years. The y-axis shows the probability of survival.
1704 KALYANI ET AL. SEPTEMBER 2012–VOL. 60, NO. 9 JAGS
levels alone, also influences levels.8 The other advantages
of HbA1c are that it can be obtained without fasting and
may be less variable with repeat testing.19 Thus, the results
of the current study provide a new perspective on a previ-
ously described relationship between hyperglycemia and
incident frailty.
It has been demonstrated that higher HbA1c levels are
cross-sectionally associated with walking difficulties.9 The
present study reports for the first time that the develop-
ment of difficulty in self-reported walking or performance-
based measures of lower extremity function is greater in
persons with HbA1c levels of 8.0% or greater than in
those with levels less than 5.5% at baseline, independent
of confounders. Objective measures may also detect pre-
clinical limitations that predict future disability.12,14
Evidence was not found of a J-shaped association
between HbA1c and incident frailty or lower extremity
outcomes, although such associations have been described
between HbA1c and mortality.16,17,20 Explanations for this
discordance include the potential relationship between
hypoglycemia and sudden death 21 unrelated to the pres-
ence of frailty. Furthermore, frailty events occurring right
before death may have been undetected in the analyses, yet
when the composite outcome of incident frailty or death
was examined, the results were unchanged (data not
shown), although smaller numbers of participants with
high HbA1c levels in the current study may have limited
the ability to detect quadratic associations.
The association between hyperglycemia and incident
frailty may be due to several factors. Similar to other studies,
the current study found that frail women were more likely to
be obese, which may be associated with chronic inflamma-
tion.22 Inflammation is further associated with lower leg
muscle mass and strength, which in turn is related to func-
tional impairment, physical disability, and frailty.12,23,24
Lower muscle function is inherent in the definition of frailty.
In addition, chronic hyperglycemia is a risk factor for car-
diovascular disease, which in turn has been associated with
frailty,25 although the current study found that hyperglyce-
mia was related to incident frailty status independent of the
potential contributions of adiposity, inflammation, and car-
diovascular disease. It also found that participants with
hyperglycemia were more likely to develop lower extremity
mobility limitations independent of confounders and that
associations were independent of potential mediators such
as peripheral arterial disease and peripheral neuropathy.3
A possible implication of these findings is that direct
pathways linking hyperglycemia to muscle loss need to be
considered. Insulin resistance and diabetes mellitus have
been associated with excessive loss of lean body mass and
muscle strength in observational studies.26,27 Insulin resis-
tance is also associated with skeletal muscle mitochondrial
dysfunction,28 which may suggest underlying pathways for
these epidemiological findings, but further studies are
needed.
Limitations of this study include the small sample size
of participants in the highest HbA1c category (8.0%),
although it was possible to discern significant associations
between HbA1c and incident frailty and lower extremity
mobility limitations in adjusted regression models. The
study included only women, limiting generalizability.
There was also high mortality, probably because of the old
Table 2. Frailty and Lower Extremity Mobility Limitations in the Women’s Health and Aging Study II, According
to Glycosylated Hemoglobin at Baseline
Glycosylated Hemoglobin Level,%
Adjusted Hazard Ratio (95% Confidence Interval)
Model 1 Model 2 Model 3 Model 4
Frailty
5.5–5.9 1.28 (0.65–2.49) 1.35 (0.69–2.65) 1.30 (0.66–2.55) 1.29 (0.65–2.55)
6.0–6.4 1.18 (0.57–2.45) 1.26 (0.59–2.67) 1.25 (0.59–2.65) 1.25 (0.58–2.69)
6.5–7.9 1.17 (0.44–2.81) 1.05 (0.41–2.7) 1.01 (0.39–2.61) 1.04 (0.40–2.70)
 8.0 3.63 (1.41–9.33) 3.16 (1.19–8.35) 3.12 (1.18–8.27) 3.33 (1.24–8.93)
Difficulty walking one-quarter of a mile
5.5–5.9 1.10 (0.59–2.05) 1.18 (0.63–2.21) 1.17 (0.62–2.20) 1.14 (0.60–2.15)
6.0–6.4 1.36 (0.71–2.61) 1.25 (0.64–2.43) 1.24 (0.64–2.41) 1.28 (0.65–2.51)
6.5–7.9 2.26 (1.05–4.87) 1.70 (0.77–3.75) 1.70 (0.77–3.75) 1.77 (0.79–3.97)
 8.0 5.03 (1.91–13.27) 2.93 (1.08–7.96) 2.91 (1.07–7.91) 3.47 (1.26–9.55)
Low walking speeda
5.5–5.9 1.04 (0.67–1.61) 1.06 (0.68–1.66) 1.04 (0.67–1.63) 1.02 (0.65–1.59)
6.0–6.4 0.95 (0.59–1.53) 0.98 (0.60–1.59) 0.91 (0.56–1.49) 0.93 (0.56–1.52)
6.5–7.9 1.25 (0.69–2.28) 1.24 (0.67–2.29) 1.12 (0.60–2.09) 0.97 (0.52–1.82)
 8.0 3.14 (1.35–7.34) 2.89 (1.23–6.81) 2.70 (1.15–6.33) 2.82 (1.19–6.71)
Low physical performanceb
5.5–5.9 0.99 (0.66–1.50) 1.01 (0.67–1.54) 1.00 (0.66–1.53) 0.97 (0.63–1.49)
6.0–6.4 1.23 (0.78–1.93) 1.24 (0.79–1.96) 1.19 (0.75–1.89) 1.19 (0.75–1.88)
6.5–7.9 1.14 (0.64–2.02) 1.13 (0.63–2.02) 1.05 (0.58–1.88) 1.06 (0.58–1.92)
 8.0 3.31 (1.43–7.69) 3.25 (1.38–7.66) 3.09 (1.31–7.28) 3.60 (1.52–8.53)
Model 1 adjusted for age, race, education. Model 2 adjusted for variables in Model 1 and body mass index. Model 3 adjusted for variables in Model 2
and interleukin-6. Model 4 adjusted for variables in Model 3 and clinical history of comorbidities (osteoarthritis, chronic obstructive pulmonary disease,
coronary artery disease, peripheral arterial disease, and peripheral neuropathy).
a Walking speed in the lowest quartile (<0.82 m/s).
b Short Performance Physical Battery score in the lowest quartile (<9).
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age of the women, although these occurred nonsystemati-
cally (data not shown). Only baseline HbA1c levels were
explored, although changes in HbA1c levels over time may
contribute to frailty status as well. Furthermore, the
majority of persons with HbA1c of 8.0% or greater had a
known history of diabetes mellitus, so it was not possible
to separate the effect of HbA1c from the presence of dia-
betes mellitus itself. As a result, the possibility that other
aspects of the diabetic state, such as the use of glucose-
lowering therapies, could contribute to frailty or that
higher HbA1c levels in older persons reflects poorer self-
care management and greater risk of adverse outcomes
cannot be excluded. Lastly, although the study focused on
an individual measure (HbA1c), recent studies have sug-
gested that deficits across multiple systems may be most
important in frailty development.29 It is likely that com-
plex interactions between dysglycemia and abnormalities
in other physiological systems contribute to the pathophys-
iology of frailty, which it is hoped will be explored in a
future study. Strengths of the current study include the
well-characterized Women’s Health and Aging Study II
cohort, use of standardized protocols, inclusion of self-
reported and performance-based measures of lower
extremity function, examination of potential nonlinear
relationships, and length of follow-up. Furthermore, use of
a long-term glycemic marker (HbA1c) minimized potential
variability in exposure.
In conclusion, this study adds to growing evidence
that hyperglycemia is independently associated with the
development of frailty and with incident lower extremity
mobility limitations. HbA1c testing may represent a practi-
cal method to screen individuals at high risk for the
development of adverse geriatric outcomes, but whether
this greater risk of adverse geriatric outcomes is primarily
related to HbA1c levels in the moderately uncontrolled
diabetic range or higher ( 8.0%) needs to be further
explored. A better understanding might provide insight
into whether clinical guidelines proposing less-aggressive
HbA1c targets in older adults with diabetes mellitus are
appropriate.30 Although the mechanism remains unclear,
direct associations between hyperglycemia and muscle loss
may contribute and should be investigated in future stud-
ies. Intervention studies are ultimately needed to explore
whether treatment of hyperglycemia may delay or prevent
the development of frailty and lower extremity limitations
in older adults.
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